Health Condition 1: null- Uncomplicated Plasmodium falciparum malaria
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum Asexual P. falciparum parasitaemia: 10,000 to 100,000/uL, determined on a thin or thick blood film Fever defined as > 37.5°C temperature or a history of fever within the last 24 hours Written informed consent (by legally acceptable representative in case of children) Willingness and ability of the patients/guardians to comply with the study protocol for the duration of the study
Exclusion criteria
Exclusion criteria: Signs of severe/complicated malaria Haematocrit Acute illness other than malaria requiring treatment For females: pregnancy, lactating Patients who have received artemisinin or a derivative or an artemisinin-containing combination therapy (ACT) within the previous 7 days History of allergy or known contraindication to artemisinins, or to the ACT to be used at the site Previous splenectomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Within one year the study is expected to produce data of the prevalence and severity of artemisinin resistance if any.Fro this Parasite clearrance time PCT will be calculated.Timepoint: 28 days followup | — |
Secondary
| Measure | Time frame |
|---|---|
| Parasite reduction rates and ratios at 24 and 48 hours by microscopy and quantitative PCR Time for parasite count to fall to 50%, 90% and 99% of initial parasite density Fever clearance time Proportion of patients with gametocytemia before, during and after treatment with artesunate, assessed at admission, on days 3, 7 and 14 Parasite molecular markers of drug resistanceTimepoint: 28 days follow up | — |
Countries
India
Contacts
National Institute of Malaria Research